Johnson & Johnson Submits sBLA to Expand Stelara Use for Pediatric Crohn’s Disease
US giant Johnson & Johnson (J&J, NYSE: JNJ) this week submitted a supplemental Biologics License...
Johnson & Johnson
Legend Biotech Plans to Disband China Sales Team Amid Carvykti Commercialization Challenges
Reports indicate that China-based Legend Biotech Corporation (NASDAQ: LEGN) plans to disband its China sales...
Johnson & Johnson Launches Tremfya IV in China for Inflammatory Bowel Diseases
US-based Johnson & Johnson (J&J; NYSE: JNJ) announced the commercial launch of Tremfya (guselkumab) intravenous...
JNJ Reveals Positive AMPLITUDE Phase III Results for Akeega in mHSPC at ASCO 2025
US giant Johnson & Johnson (J&J, NYSE: JNJ) announced initial results from the Phase III...
Bio-Thera Solutions’ BAT2206 Biosimilar of Stelara Gains FDA Approval
Guangzhou-based Bio-Thera Solutions Ltd. (SHA: 688177) announced that it has received Biologic License Application (BLA)...
J&J’s Tremfya Approved for Ulcerative Colitis in China
US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received marketing approval...
European Commission Approves J&J’s Tremfya for Crohn’s Disease Treatment
Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission (EC) has approved Tremfya...
Johnson & Johnson’s Imaavy Gains FDA Approval for Generalized Myasthenia Gravis
US giant Johnson & Johnson (J&J, NYSE: JNJ) unveiled a market approval in the United...
Johnson & Johnson’s TAR-200 Shows Promising Results in Phase IIb SunRISe-1 Study for Bladder Cancer
US giant Johnson & Johnson (J&J; NYSE: JNJ) has released the first results from Cohort...
Johnson & Johnson’s Rybrevant Gains NMPA Approval for Expanded Lung Cancer Indication
US giant Johnson & Johnson (J&J; NYSE: JNJ) announced that it has received another indication...
Johnson & Johnson’s Tremfya Approved by EC for Ulcerative Colitis Treatment
US giant Johnson & Johnson (J&J; NYSE: JNJ) announced that it has received regulatory approval...
Johnson & Johnson Reports Q1 2025 Revenue Growth, Led by Innovative Medicines and MedTech
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) reported Q1 2025 revenues of USD...
Johnson & Johnson Launches Rybrevant in China for EGFR Exon 20 Insertion Mutation Lung Cancer
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has officially launched Rybrevant (amivantamab), an...
J&J’s Rybrevant SC Formulation Approved by EC for NSCLC Treatment
The European Commission (EC) has approved the subcutaneous (SC) formulation of Johnson & Johnson’s (J&J,...
J&J’s Darzalex SC Formulation Approved for Newly Diagnosed Multiple Myeloma
Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received clearance from the European...
Johnson & Johnson Completes Acquisition of Intra-Cellular Therapies
US-based Johnson & Johnson (NYSE: JNJ) announced the completion of its acquisition of fellow American...
Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy’s for Biosimilar Commercialization
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with India-headquartered Dr. Reddy’s...
Johnson & Johnson Pledges USD55 Billion for US Expansion, Focusing on Manufacturing and R&D
US giant Johnson & Johnson (J&J, NYSE: JNJ) has committed to investing over USD 55...
Johnson & Johnson’s Tremfya Gains FDA Approval for Crohn’s Disease Treatment
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has announced receiving clearance from the...
Johnson & Johnson’s Nipocalimab Receives FDA Fast Track Designation for Sjögren’s Disease
US giant Johnson & Johnson (J&J; NYSE: JNJ) announced receiving Fast Track designation (FTD) from...